Summary:
- Gilead Sciences' investigational injectable HIV prevention drug, lenacapavir, has demonstrated a 96% reduction in HIV infections compared to a daily oral HIV prevention pill in a late-stage clinical trial.
- The trial enrolled over 4,500 cisgender men and transgender women who have sex with men, a population at high risk of contracting HIV. The results show lenacapavir's potential to be a game-changer in HIV prevention.
- If approved, lenacapavir would be the first new HIV prevention method in over a decade and could significantly improve adherence and access to HIV prevention, especially for those who struggle with daily oral medication.